Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
W. Timothy Garvey(University of California, Santa Cruz), Anuj Bhargava(Iowa Diabetes and Endocrinology Research Center), José Francisco Kerr Saraiva(British Heart Foundation), Miguel Nasser Hissa, Ania M. Jastreboff(Yale University), Ametov As, Ignacio MacKinnon, Ghanshyam Goyal, Imane Benabbad(Eli Lilly (United States)), Senan Sultan, Franklin Ábalos(Eli Lilly (United States)), Denise Reis Franco, Alex Gonzalez, Diego Aizenberg(University of Glasgow), George Freeman, P. Costanzo, Federico C. Pérez Manghi, Alan A. Parsa, Marina V. Shestakova, Е. А. Трошина, Maria H Vidotti, I‐Te Lee(Chang Gung University), Cesar Javier Zaidman, Shih‐Te Tu, Naveed Sattar(University of Glasgow), Chien‐Ning Huang(Chung Shan Medical University Hospital), Klara R. Klein, Juan P. Frías(National Research Institute), Chwen-Yi Yang, Н. В. Ворохобина, Sriram Machineni, Otavio Moratto, Elena Khaykina, Juan Otero-Martinez(Velocity Clinical Research (United States)), Shuyu Zhang(Soochow University), Satoshi Inoue, Taro Asakura, Nadia N. Ahmad(Eli Lilly (United States)), Sreenivasa Murthy, Mathijs C. Bunck(Eli Lilly (United States)), Yoshimitsu Yamasaki(Osaka University), Marisa L. Vico, Huzhang Mao(Eli Lilly (United States)), Nobuyuki Sato, Horng‐Yih Ou(University College Dublin), Breno B. Alves, Carel W. le Roux(University College Dublin)
Cited by 676
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
|The Lancet Diabetes & Endocrinology|2019|1.6k